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S U M M A R Y
Objectives: An outbreak of joint and cutaneous infections among patients who had been injected at a
single clinic in South Korea was investigated.
Methods: In this retrospective case–control study, 61 cases were diagnosed based on symptoms and
signs of septic arthritis or cutaneous infection that developed after injections at the clinic between April
and September 2012; 64 controls were investigated by administering questionnaires on risk factors and
analyzing the clinic medical records. An environmental investigation was performed, and clinical
specimens of the cases were analyzed by pulsed-ﬁeld gel electrophoresis.
Results: All cases were injected with triamcinolone. A greater number of triamcinolone injections (adjusted
odds ratio 4.3, 95% conﬁdence interval 1.5–12.1 for six or more visits, compared with one or two visits) was
associated with the development of an infection. In the clinic, only the triamcinolone injection was prepared
by mixing with lidocaine and normal saline, and an alcohol swab was prepared using boiled tap water by
members of the clinic staff. Although injected medications and environmental cultures were not found to be
responsible, a single strain of Mycobacterium massiliense was isolated from the affected sites of 16 cases.
Conclusions: Repeated injection of triamcinolone contaminated with NTM from the clinic environment
may have caused this post-injection outbreak.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Non-tuberculous mycobacteria (NTM) are deﬁned as myco-
bacteria excluding Mycobacterium tuberculosis and Mycobacterium
leprae. NTM are ubiquitous in the environment and there are more
than 65 different species, including Mycobacterium massiliense and
Mycobacterium abscessus.1 They can cause opportunistic infec-
tions,2 and can lead to pulmonary, lymph node, skin and soft tissue,
and bone and joint infections. Such infections result from
environmental exposure (soil, dust, water), contaminated materi-
als, or invasive procedures (medical devices, multi-dose vials).3* Corresponding author.
E-mail address: bjpark@snu.ac.kr (B.-J. Park).
http://dx.doi.org/10.1016/j.ijid.2015.05.018
1201-9712/ 2015 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Corticosteroid injections are frequently used for the local
treatment of musculoskeletal disorders, including osteoarthritis,
synovitis, bursitis, tendonitis, back pain, etc.4–6 Relatively mild
adverse effects, including swelling, pain, steroid ﬂare, hot ﬂashes,
mild skin discoloration, skin atrophy, and cellulitis, have been
reported in prospective and retrospective studies, although there
have been a few case reports of atypical Mycobacterium soft tissue
infection, tendon rupture, and ischemia.7
In October 2012, 27 patients were hospitalized due to septic
arthritis caused by a presumed NTM infection, after having been
given triamcinolone injections at a single clinic. These cases were
reported to the Korea Institute of Drug Safety and Risk Manage-
ment (KIDS) as a spontaneous adverse drug events report. Since
such infections are difﬁcult to diagnose and NTM are difﬁcult to
isolate and are resistant to multiple antibiotics,8 it is important tociety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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and provide appropriate treatment. Therefore, an epidemiological
investigation team was assembled, consisting of staff from KIDS,
the Korea Food and Drug Administration (KFDA; Ministry of Food
and Drug Safety (MFDS) from 2013), the Korea Center for Disease
Control and Prevention (KCDC), and the local public health
authorities (the community public health center and local city
government), supervised by the Ministry of Health and Welfare
(MoHW). An epidemiological investigation was performed imme-
diately to identify whether the infection was due to the injected
drugs or other factors, and to assess the risk factors for post-
injection NTM infection. A case–control study was performed to
compare exposure to injections and other environmental factors
between patients with NTM infections and healthy subjects.
2. Methods
2.1. Case detection
Initially, 27 cases were reported to KIDS as a spontaneous
adverse drug event by the physician at the clinic. During a site visit,
the clinic medical charts were investigated to identify other
possible cases of infection. Additional cases had to be found from
other sources because a medical assistant employed by the clinic
intentionally destroyed documents containing patient contact
information. At ﬁrst, the electronic medical chart system was
searched and the names and personal identiﬁcation numbers of
eligible patients with orders for any injection at the clinic between
April and September 2012 were identiﬁed. Every member of the
Korean population has his/her own unique personal identiﬁcation
number. Using this information, in collaboration with a police
investigation, three postal questionnaire surveys were performed
(November 2012, December 2012, May 2013), asking patients
whether they had experienced adverse events after the injection at
the clinic. Furthermore, two healthcare utilization databases were
linked: the Korea Health Insurance Review and Assessment Service
(HIRA) and the National Health Insurance Service (NHIS) claims
database (December 2011 to June 2013). Using these databases,
patients who had visited medical institutions due to suspected
infections were identiﬁed using the following diagnostic codes:
tuberculosis of skin and subcutaneous tissue (ICD-10, A18.4); other
mycobacterial infections (A31.8), mycobacterial infection, unspec-
iﬁed (A31.9); cutaneous abscess, furuncle and carbuncle (L02),
cellulitis (L03); other speciﬁed local infections of skin and
subcutaneous tissue (L08.8); pyogenic arthritis, unspeciﬁed
(M00.9); tuberculous arthritis (M01.1); inﬂammatory polyarthro-
pathy (M06.4); rheumatoid arthritis, unspeciﬁed (M06.9); villo-
nodular synovitis (pigmented) (M12.2); internal derangement of
knee, unspeciﬁed (M23.9); effusion of joint (M25.4); infection
following a procedure, not elsewhere classiﬁed (T81.4).
After identifying potential cases from the various sources, cases
for this epidemiological investigation were identiﬁed through
interviews and medical chart review. A case patient was a patient
with an abscess, mass, pain, redness, swelling, or a burning
sensation, who was diagnosed with a potential NTM infection at a
medical institution (either inpatient or outpatient) between April
and September 2012 after exposure to any injections at the clinic.
2.2. Selection of controls
Among patients who had been given injections at the clinic
between April and September 2012, those without any symptoms
or signs of NTM infection were assumed to be potential controls.
The absence of NTM infection was assessed by (1) no diagnostic
codes for a suspected infection in the HIRA or NHIS claims
database, and (2) a response indicating no signs or symptoms inthe postal survey or direct contact interview. Those who agreed to
the request for enrollment and who completed the questionnaire
were included as controls in the case–control study.
2.3. Data collection
To deﬁne the patients who had visited the clinic during April to
September 2012, the electronic medical charts were reviewed and
the exposure status of those who had received any injections was
determined. For the case–control study, data were collected by
interview using a structured questionnaire during the epidemio-
logical investigation. The questionnaire included information on
patient characteristics, risk factors (age, sex, smoking, alcohol
consumption, hygiene, and comorbidities), exposures (visit to the
clinic, injection procedure, and site of injection), and adverse
events for the cases (symptoms of infection, date of onset, medical
visits due to infection, and site of infection). For the cases, the
medical charts were reviewed for information about the treatment
of infections, noting the diagnosis of the signs and symptoms,
laboratory tests, synovial ﬂuid examination, surgery modality and
location, antibiotic treatment, and NTM species identiﬁed. The data
from the completed questionnaires and medical records were
entered into a computerized database.
2.4. Evaluation of injection practices and environmental/ laboratory
investigations
The physician and medical assistants at the clinic were
interviewed about their injection procedures. However, it was
impossible to investigate the medical assistant who gave the
injections, because we were not able to contact him. KFDA staff
ascertained the manufacturer and lot numbers of the injections,
and performed an evaluation of the microorganisms present in the
injection medications and syringes. Environmental specimens
were taken, including empty vials, injection needles, alcohol
swabs, surfaces, and water to culture for mycobacteria. In addition,
the clinical specimens of 18 NTM-positive cases from six hospitals
were examined using pulsed-ﬁeld gel electrophoresis (PFGE) by
the KCDC.9
2.5. Statistical analysis
Descriptive statistics were used to illustrate the characteristics
of the study population. For the cases, the incubation period
between the last injection of triamcinolone and symptoms of
infection was calculated. The odds ratios (ORs) and their 95%
conﬁdence intervals (95% CI) for infection according to exposure to
various injections, including triamcinolone, betamethasone, meth-
ylprednisolone, hyaluronate, piroxicam (non-steroidal anti-in-
ﬂammatory), tramadol (analgesic), pridinol (muscle relaxant),
Arnica tincture, and Aconitum tincture (combined anti-inﬂamma-
tory injection), were calculated using logistic regression. The ORs
and their 95% CI of factors associated with infection were also
calculated. The number of administrations of each injection, the
calendar month of last injection, and injections in speciﬁc periods
were included as factors. The statistical analysis was performed
using SAS statistical application software (release 9.3; SAS
Institute, Inc., Cary, NC, USA).
2.6. Ethics statements
This study was waived from review by the Institutional Review
Board of the Korea Institute of Drug Safety and Risk Management.
The collection of patient information using the HIRA and NHIS
databases and contacting them via police investigation was
endorsed by the Ministry of Security and Public Administration
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Informed consent was collected from cases and controls who we
were able to contact and who responded to an interview.
3. Results
3.1. Characteristics of the study population
Among the 1264 patients who visited the clinic between April
and September 2012, 244 were administered one or more
injections at the clinic. Among these, 118 patients were excluded
from the study population as it was not possible to contact them or
they refused to be contacted (n = 5 for patients assumed to have
symptoms of NTM infection, n = 113 for patients assumed to have
no symptoms or signs of NTM infection). Another patient who had
a history of NTM infection in the previous calendar year was also
excluded from the study population. A total of 66 potential cases
were identiﬁed by spontaneous reports from patients and
physicians treating potential cases, the HIRA claims databases,
and the postal survey; the response rate to three administrations of
the postal survey was 52.7%. However, it was not possible to assess
whether ﬁve patients ﬁt the case deﬁnition because their contact
information was unavailable or they refused to participate. Thus,
61 subjects were included in the analysis, among whom 29 were
conﬁrmed as NTM-positive in the treatment hospitals and
32 suspected cases had clinical symptoms of NTM infection
diagnosed by clinicians. A total of 164 patients were assumed to be
without NTM infection according to the HIRA and NHIS databases.
However, there were 99 patients who could not be contacted in
order to carry out the questionnaire interview, and one patient had
a history of NTM infection just before the study period. The ﬁnalFigure 1. Selection of the case–control study population from patients who visitepopulation for the case–control analysis was 61 cases and
64 controls (Figure 1).
When comparing cases with NTM infection and controls among
those who were exposed to the injections under investigation, the
cases did not differ signiﬁcantly from the control group in terms of
age, alcohol consumption, BMI, and frequency of showering and
bathing on the date of injection. However, the case group included
more females and non-smokers (p < 0.05) (Table 1).
The epidemic curve for the 61 cases is shown in Figure 2. The
date of onset of signs or symptoms of NTM infection stretched from
May 2012 to February 2013. The most frequently reported calendar
month was September 2012 (n = 27). The dates of injection were
distributed from May to September 2012. Because each case was
given a triamcinolone injection one or more times (mean 6.1,
standard deviation 4.5, range 1–22) during the study period, it was
not possible to calculate the time gap between the date of the
suspected injection and the date of illness onset. Each case had one
or more sites of infection. The location of symptoms among cases
was as follows: the knee joint in 50 cases (82.0%), the hip in nine
cases (14.8%), the back in eight cases (13.1%), the lumbus in six
cases (9.8%), and the shoulder in ﬁve cases (8.2%), etc. When the
clinical progress of cases was assessed in August 2013, 13 cases
(21.3%) had recovered, 46 cases (75.4%) were undergoing outpa-
tient care with antibiotic treatment, and two cases (3.3%) had been
hospitalized. Antibiotic susceptibility testing showed that the NTM
strains were sensitive to amikacin, clarithromycin, and linezolid.
3.2. Risk of NTM infection
Among the 1264 patients who visited the clinic between April
and September 2012, all 61 cases occurred among the 229 patientsd the clinic. *HIRA: Korea Health Insurance Review and Assessment Service.
Table 1
Characteristics of cases and controls
Cases (n = 61) Controls
(n = 64)
p-Valuea
n % n %
Sex
Male 12 19.7 28 43.8 0.004
Female 49 80.3 36 56.2
Age, years
Mean  SD 55.1  9.7 51.6  13.4 0.098
Range 29–75 13–80
10–19 0 0 2 3.1 0.457
20–29 1 1.6 4 6.3
30–39 2 3.3 4 6.3
40–49 13 21.3 13 20.3
50–59 29 47.6 23 35.9
60–69 11 18 15 23.4
70–80 5 8.2 3 4.7
Smoking
Current 5 8.2 15 23.4 0.043
Ex 3 4.9 6 9.4
No smoking 50 82 43 67.2
Missing 3 4.9 0 0
Alcohol consumption
Current 17 27.9 25 39.1 0.199
Ex 6 9.8 2 3.1
No drinking 35 57.4 37 57.8
Missing 3 4.9 0 0
BMI, kg/m2
Mean  SD 23.1  2.5 23.1  2.5 0.953
Range 17.1–28.0 17.8–29.1
<18.5 3 4.9 4 6.3 0.836
18.5 to <23.0 25 41 28 43.8
23.0 31 50.8 29 45.3
Missing 2 3.3 3 4.7
Frequency of shower/bath
1/day 36 59 44 68.8 0.697
2–3 per week 17 27.9 15 23.4
1 per week 5 8.2 4 6.3
Missing 3 4.9 1 1.5
Frequency of changing underwear
1/day 41 67.2 56 87.5 0.011
2–3 per week 12 19.7 7 10.9
1 per week 5 8.2 0 0
Missing 3 4.9 1 1.6
Bath on injection date
Yes 35 57.4 40 62.5 0.636
No 13 21.3 16 25
Cannot remember 0 0 2 3.1
Missing 13 21.3 6 9.4
SD, standard deviation; BMI, body mass index.
a p-Values were calculated by Chi-square test, Fisher’s exact test, or the Student’s
t-test, as appropriate.
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occurred in the absence of exposure to triamcinolone injection.
The results of the case–control analyses are presented in
Table 2. After adjusting for potential confounders, a higher number
of visits to the clinic for corticosteroid injections showed a
signiﬁcantly increased risk of infection (aOR 4.3, 95% CI 1.5–12.1
for six or more visits, compared with one or two visits). Other
injections including hyaluronate, piroxicam, pridinol, tramadol,
and arnica tincture did not show a signiﬁcant association with the
infection. Regarding the calendar month of triamcinolone injec-
tion, the administration of the last injection in August (aOR 20.4,
95% CI 2.0–206.6) was more associated with the development of
the infection compared with April (Table 2).
3.3. Process of preparing and applying injections
Interviews with the physician, cases, and controls indicated
that the process of preparing and applying injections was asfollows. After administering a massage therapy known as ‘Chuna’, a
medical assistant prepared the injection agent. The triamcinolone
injection agent was a mixture of approximately 0.5 ml of
triamcinolone from a 1-ml container, 1 ml of normal saline from
a 20-ml container, and 1 ml of lidocaine from a 20-ml container.
After mixing the agent, the remaining triamcinolone solution was
stored in a multidose vial at a normal temperature or in a
refrigerator for later use. Other injections were sealed in each
ampoule and not mixed with normal saline. The hyaluronate
injection was prepared as a pre-ﬁlled syringe. The nursing assistant
gave the injection at multiple sites, including intra-articular, peri-
articular, and others, using a single syringe, without wearing
gloves, after cleaning the skin with a cotton ball soaked in 70%
alcohol that was diluted with boiled tap water.
3.4. Environmental/ laboratory investigations
An investigation of the injection medication and syringe found
no microorganisms. Although the clinic environment, including
the method of preparing injections and the site of the procedure,
was found not to be appropriately sterilized, no NTM were
identiﬁed in any environmental specimen. However, the following
species of NTM were identiﬁed in the specimens from 29 of the
61 cases: M. massiliense (n = 21), M. abscessus (n = 6), and not
speciﬁed (n = 2). Molecular typing (PFGE) of the 18 M. massiliense
strains from six hospitals showed identical results (100%) for
16 isolates and similar results for two isolates (97.9% and 96.0%,
respectively) (Figure 3). The presence of identical M. massiliense
isolates in patients admitted to various hospitals implies a high
possibility of a common source of infection.
4. Discussion
Although identical NTM isolates from the cases implied
exposure to a common infection source, the environmental
samples gave negative culture results and the exact infection
source was not determined. However, the epidemiological
evidence led us to suppose that the infections were linked to
contaminated injections, occurring in the storage of the injection
agents, in the process of mixing the injection agents, or in the
injection procedure. Furthermore, considering the mean incuba-
tion period of 18.3 days estimated in the present population, and
the fact that the date of occurrence of the adverse events in the
cases was spread widely from May 2012 to February 2013, it is
likely that the infection was caused by continuous exposure to
certain environmental sources.
The infection showed a speciﬁc association with triamcinolone
injection at a speciﬁc clinic. All the cases were exposed to
triamcinolone injections. However, there was no report of infection
among other patients who were treated with triamcinolone from
the same lot at other medical institutions. In addition, a laboratory
test of the triamcinolone gave a negative result. If the outbreak had
been due to contaminated drugs, the infection would have
occurred in a number of different medical institutions. For
example, in 2012, contaminated glucocorticoid medication from
a single compounding pharmacy caused a multistate outbreak of
fungal infection in the USA; over 700 cases of infection were
identiﬁed in 20 states.10
Regarding the source of infection, the rapidly growing
mycobacteria could have been present in air or tap water3 and
likely contaminated cotton balls, the injection agent, or other
devices. Based on the interviews with the clinic physician and
assistant, as well as an environmental investigation, it was
apparent that the staff prepared the alcohol for use as a
disinfectant themselves, which included the use of boiled tap
water (not normal saline) and mixing this with 99% ethanol. In
Figure 2. Epidemic curve and longitudinal distribution of date of triamcinolone injection and onset of illness for 61 cases. *Each case had one or more triamcinolone injections
(mean  SD = 6.1  4.5; median (range) = 5 (1–22)).
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lone with normal saline and lidocaine, and some of the remaining
agent. After being administered to a patient, the mixed agent was
stored at normal temperature or in a refrigerator until its next
use.Table 2
Numbers and months of triamcinolone injections, injections with other agents, and th
Cases (n = 61) Controls (n = 64) 
n (%) n (%) 
No. of triamcinolone injectionsb
1–2 13 (21.3) 32 (50.0
3–5 23 (37.7) 21 (32.8
6 25 (41.0) 11 (17.2
Hyaluronate injection 23 (37.7) 11 (17.2
Piroxicam injection 58 (95.1) 55 (85.9
Pridinol injection 58 (95.1) 59 (92.2
Tramadol injection 26 (42.6) 28 (43.7
Arnica tincture injection 10 (16.4) 2 (3.1)
Aconitum tincture injection 2 (3.3) 0 (0.0)
Betamethasone injection 1 (1.6) 1 (1.6)
Methylprednisolone injection 1 (1.6) 0 (0.0)
Last injection date of triamcinolone
April 1 (1.6) 8 (12.5
May 3 (4.9) 19 (29.7
June 3 (4.9) 11 (17.2
July 7 (11.5) 9 (14.1
August 30 (49.2) 7 (10.9
September 17 (27.9) 10 (15.6
Triamcinolone injection in speciﬁc period
Apr–May 4 (6.6) 27 (42.2
Jun–Jul 6 (9.7) 5 (7.8)
Apr–May, Jun–Jul 4 (6.6) 15 (23.4
Aug–Sep 12 (19.7) 7 (7.9)
Apr–May, Aug–Sep 4 (6.6) 1 (1.6)
Jun–Jul, Aug–Sep 19 (31.1) 5 (7.8)
Apr–May, Jun–Jul, Aug–Sep 12 (19.7) 4 (6.3)
NTM, non-tuberculous mycobacteria; OR, odds ratio; CI, conﬁdence interval.
a ORs were estimated using a logistic regression model, adjusting for age, sex, smok
b The p-value for trend calculated by likelihood test for trend was 0.435.All cases were given a Chuna massage by a medical assistant.
Chuna is a manual therapy widely used in Korean traditional
medicine practice for the treatment of musculoskeletal pain; it
uses techniques including thrust, mobilization, distraction of
joints, and soft tissue release.11 The massage does not include anye risk of NTM infection: case–control analysis
Crude Adjusted
OR (95% CI) ORa (95% CI)
) 1 1
) 2.70 (1.12–6.47) 2.91 (1.07–7.85)
) 5.60 (2.17–14.59) 4.25 (1.49–12.13)
) 2.92 (1.27–6.69) 1.27 (0.45–3.63)
) 3.16 (0.81–12.30) 3.38 (0.52–21.86)
) 1.64 (0.37–7.17) 5.17 (0.52–51.06)
) 0.96 (0.47–1.94) 1.03 (0.38–2.77)
 6.08 (1.27–29.00) 4.28 (0.66–27.90)
 - -
 1.05 (0.06–17.17) -
 - -
) 1 1
) 1.26 (0.11–14.05) 0.93 (0.08–11.37)
) 2.18 (0.19–25.02) 1.66 (0.13–20.96)
) 6.22 (0.62–62.16) 2.53 (0.22–28.87)
) 34.29 (3.67–320.68) 20.36 (2.01–206.58)
) 13.6 (1.48–125.31) 8.47 (0.81–88.09)
) 1 1
 8.1 (1.66–39.51) 3.79 (0.68–21.3)
) 1.8 (0.39–8.25) 1.61 (0.33–7.89)
 11.57 (2.84–47.12) 12.23 (2.65–56.52)
 27 (2.38–306.66) 19.45 (1.36–278.96)
 25.65 (6.08–108.24) 17.76 (3.83–82.32)
 20.25 (4.33–94.81) 13.69 (2.61–71.89)
ing status, and frequency of changing underwear.
Figure 3. Molecular strain typing of isolates from 18 cases, by pulsed-ﬁeld gel electrophoresis (PFGE).
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culture medium for M. massiliense. Inadequate sterilization of the
needles or the puncture site was also suspected as a route of
transmission. After the Chuna massage, the injection site was
sterilized with a cotton ball soaked in diluted ethanol, and then the
drugs were injected at multiple sites using a single syringe with
one needle, without the use of gloves. The process of preparing the
cotton balls soaked in alcohol may also have been a source of
infection. In an outbreak of M. abscessus infection after trigger point
injections and epidural blocks at a clinic in Korea in 2009,
inadequate sterilization of the injection sites, inadequate equip-
ment sterilization using the autoclave, and improper preparation
of the injection drugs and septic techniques were hypothesized as
possible sources of the outbreak.12 Tiwari et al. (2003) reported an
outbreak of post-injection infection that was caused by diluted
benzalkonium chloride, which was used as the disinfectant
although this antiseptic agent was not effective against M.
abscessus.13
Although it was also difﬁcult to identify the exact source of
infection and mode of transmission in these previous outbreak
investigations, most previously reported NTM infections were
presumed to be due to extrinsic contamination. In the case of an
outbreak of M. abscessus infection after intramuscular injection in
China, contamination occurred due to the inappropriate reuse of
needles in the rubber septum of 100-ml multiple-dose normal
saline bottles, which were initially assumed to be contaminated via
tap water.14 In addition, in an outbreak of M. massiliense after
intramuscular injections in Icheon, Korea in 2004, contaminated
multidose normal saline from an unknown extrinsic source was
suggested as the causative agent.15
There have been prior reports of NTM infection after medical
procedures. Two outbreaks of M. abscessus after acupuncture havebeen reported in Korea. In the ﬁrst outbreak in Seoul in 2001, the
exact source of infection was not determined.16 However, in the
second outbreak in Ansan in 2008, the contaminated diluted
glutaraldehyde solution that was used to disinfect the physical
therapy devices was identiﬁed as the source of infection.17 M.
massiliense infection after arthroscopic and laparoscopic proce-
dures,18 M. massiliense and Mycobacterium bolletii infection after
laparoscopic surgeries and cosmetic procedures,19 and M. massi-
liense infection after video-assisted surgery20 have been reported
in Brazil. A report of pedicure-associated infection due to the
Mycobacterium chelonae/abscessus group was reported in the USA
in 2011.21 NTM infection can even occur in a non-invasive
environment. Cutaneous M. massiliense infection among seven
day-spa workers, without any preceding invasive procedure, has
been reported in Japan.22
Even though the infection is assumed to have originated from
an environmental source, not all of the patients who were given
injections were affected. The increased risk of infection when the
triamcinolone injection was administered in August suggests that
the high temperature and humidity may have ampliﬁed the
possibility of infection from the contaminated environment. Risk
factors for septic arthritis such as advanced age, rheumatoid
arthritis, osteoarthritis, immunosuppressive therapies, and diabe-
tes mellitus may have impacted the incidence of NTM infection
among patients treated in the clinic.23
Multiple cases of septic arthritis due to M. massiliense
infection were identiﬁed in this outbreak. Several patients had
experienced the irreversible loss of joint function and had
undergone joint replacement surgeries. A study performed on
septic arthritis across all hospitals in Iceland from 1990 to
2002 reported that an increased number of intra-articular
steroids and joint-viscous supplements increased the incidence
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adults were iatrogenic.24
In the present investigation, patients who were injected with
triamcinolone multiple times showed an increased risk of
infection. Most patients were told to visit the clinic every week,
and were given triamcinolone injections. This pattern of frequently
repeated injections may have made the patients prone to infection;
even administered into the intra-articular space, the glucocorticoid
can be absorbed systemically, with deleterious effects on the
hypothalamic–pituitary–adrenal (HPA) axis, resulting in adrenal
suppression.25 The risk of infection was increased when hyalur-
onate injections were co-administered (data not shown). Concom-
itant injection may have increased the chance of exposure to
sources of infection. In addition, patients who were administered
hyaluronate, which is used for viscosupplementation in arthritis of
the knee in order to restore viscosity and elasticity of the synovial
ﬂuid,26 may have had a more severe disease status, carrying a
higher risk of infection. Thus, confounding by severity of disease
remains a possibility.
There were several limitations in identifying the exact
contamination source. Due to the delay in the launch of the
investigation after the adverse event occurrence and report, the
environment of the clinic had been altered, and our ability to
acquire specimens was limited. It was not possible to contact many
patients who were treated in the clinic because of the intentional
destruction of documents containing patient information at the
clinic, and we were not able to link the clinic patient list to other
databases containing contact information due to the strict Personal
Information Protection Act in Korea. We were not able to contact
the medical assistant who administered the injections. Therefore
the medical assistant’s specimen was not included in the
environmental investigation and information on his living condi-
tions or socioeconomic status was not collected. In addition, we
were not able to collect all clinical specimens from the NTM-
positive cases because of delayed contact with the hospitals. Based
on the results of each hospital’s isolation of NTM species, the
majority of NTM cases were identiﬁed as M. massiliense, but some
were identiﬁed as M. abscessus. M. abscessus sensu stricto (also
called M. abscessus), M. massiliense, and M. bolletii are very closely
related and cause a similar spectrum of human infections; these
three species are commonly called the M. abscessus complex.27,28
Since M. massiliense is genetically close to M. abscessus, some
isolates may have been misclassiﬁed. In spite of the recommenda-
tion to identify isolates of M. abscessus to the subspecies level,29
some clinical laboratories may not have fully identiﬁed the M.
abscessus subspecies massiliense. Finally, information bias regard-
ing the injection procedures at the clinic was a possibility because
the participants of this investigation had already heard about the
outbreak of infection through the news media; however, survey
answers on the injection procedure did not differ between cases
and controls.
A recent whole-genome sequencing and epidemiological study
revealed that the M. abscessus subsp. massiliense strains from
distant epidemics are genotypically highly related, which suggests
patient-to-patient transmission.30,31 However, in the present
investigation, we were not able to clarify the possibility of direct
patient-to-patient transmission because of the lack of evidence
from laboratory tests.
Despite the reports of the possibility of NTM infection from
extrinsic contamination, outbreaks of NTM infection in healthcare
settings occur regularly. In order to prevent epidemics of NTM
infection after injections, it is necessary to educate clinicians on the
safe use of intra-articular steroid injections, to observe infection
control standards when mixing agents with normal saline, to
sterilize the injection site adequately, and to avoid using single
vials of injection agents on multiple patients.32,33Acknowledgements
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